KROS

Over the past six months, Keros Therapeutics' stock has been impacted by several events. The company reported a net loss of $23.5 million for Q4 2025 and a net income of $87.0 million for the full year 2025, driven by revenue from a license agreement with Takeda. Keros completed a cash tender offer to repurchase approximately 10.95 million shares at $17.75 per share. The company presented additional Phase 1 clinical data for rinvatercept (KER-065) at the 2026 MDA Clinical & Scientific Conference and announced a collaboration with the Sean M. Healey & AMG Center for ALS. Charles Newton was appointed to Keros' board of directors, and Esther Cho was promoted to Chief Legal Officer. Keros' CEO presented at several healthcare conferences in late February and March 2026. KROS shares decreased by 40.7% from January 1, 2026, to May 8, 2026, trading at $12.07.